SCHEMBL3222576

SCHEMBL3222576

COC(=O)c1cccc2c1ccn2N

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR4A2 P43354 3/20 0.50
KMT2A Q03164 8/20 0.48
ALDH1A1 P00352 3/20 0.48
MAPT P10636 2/20 0.48
MEN1 O00255 3/20 0.48
CFTR P13569 1/20 0.46
HSD17B10 Q99714 1/20 0.46
HSP90AA1 P07900 1/20 0.45
KDM4E B2RXH2 2/20 0.44
THRB P10828 1/20 0.44
GAA P10253 1/20 0.44
MYC P01106 1/20 0.44
POLB P06746 1/20 0.44
LMNA P02545 2/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
TSHR P16473 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.42
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA5A P35218 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28280848 0.84 NR4A2 (0.50) NR4A2KMT2AALDH1A1MAPTMEN1
SCHEMBL31607540 0.82 NR4A2 (0.64) NR4A2KMT2AALDH1A1MAPTMEN1
SCHEMBL701556 0.82 NR4A2 (0.64) NR4A2KMT2AALDH1A1MAPTMEN1
SCHEMBL11218801 0.81 NR4A2 (0.50) NR4A2KMT2AALDH1A1MAPTMEN1
SCHEMBL28069774 0.81 NR4A2 (0.50) NR4A2KMT2AALDH1A1MAPTMEN1
SCHEMBL13936213 0.79 NR4A2 (0.69) NR4A2KMT2AALDH1A1MAPTMEN1
SCHEMBL13824516 0.78 NR4A2 (0.67) NR4A2KMT2AALDH1A1MAPTMEN1
SCHEMBL7507425 0.78 NR4A2 (0.48) NR4A2KMT2AALDH1A1MAPTMEN1
SCHEMBL16116199 0.78 EZH2 (0.49) NR4A2KMT2AALDH1A1MAPTMEN1
SCHEMBL13209354 0.78 MYC (0.49) NR4A2KMT2AALDH1A1MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2142516-B1 PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS SANOFI SA (FR) 2012-12-26 EP disclosed
US-8258130-B2 Pyrimidine hydrazide compounds as PGDS inhibitors SANOFI (FR) 2012-09-04 US disclosed
US-20100048568-A1 PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS SANOFI-AVENTIS (FR) 2010-02-25 US disclosed
EP-2142516-A1 PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS Sanofi-Aventis (FR) 2010-01-13 EP disclosed
WO-2008121670-A1 PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS SANOFI-AVENTIS (FR) 2008-10-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048568-A1 PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS HRH2, HRH1, HRH4 NR4A2 559/4885KMT2A 3378/4885ALDH1A1 298/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.